Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This is a multicenter, Phase IIIb, randomized, double-blind, active-controlled, parallel-group, comparative study.
The objectives of this study are:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| formoterol fumarate inhalation solution | Drug |
| Measure | Description | Time Frame |
|---|---|---|
| The primary efficacy endpoint will be the standardized area under the curve for FEV1 (FEV1 AUC0-3) over the 3-hour assessment period at End Study (Week 6/ET). | 6 weeks |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Nicola A Hanania, MD | Baylor College of Medicine | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Clinical Research Site | Mobile | Alabama | 36695 | United States | ||
| Clinical Research Site |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 19537837 | Result | Hanania NA, Boota A, Kerwin E, Tomlinson L, Denis-Mize K. Efficacy and safety of nebulized formoterol as add-on therapy in COPD patients receiving maintenance tiotropium bromide: Results from a 6-week, randomized, placebo-controlled, clinical trial. Drugs. 2009 Jun 18;69(9):1205-16. doi: 10.2165/00003495-200969090-00005. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Phoenix |
| Arizona |
| 85006 |
| United States |
| Clinical Research Site | DeLand | Florida | 32720 | United States |
| Clinical Research Site | Atlanta | Georgia | 30330 | United States |
| Clinical Research Site | Livonia | Michigan | 48152 | United States |
| Clinical Research Site | Saint Charles | Missouri | 63301 | United States |
| Clinical Research Site | St Louis | Missouri | 63141 | United States |
| Clinical Research Site | Albany | New York | 12205 | United States |
| Clinical Research Site | North Syracuse | New York | 13212 | United States |
| Clinical Research Site | Williamsville | New York | 14221 | United States |
| Clinical Research Site | Toledo | Ohio | 45560 | United States |
| Clinical Research Site | Medford | Oregon | 97504 | United States |
| Clinical Research Site | Portland | Oregon | 97213 | United States |
| Clinical Research Site | Greenville | South Carolina | 29615 | United States |
| Clinical Research Site | Spartanburg | South Carolina | 29303 | United States |
| Clinical Research Site | San Antonio | Texas | 78229 | United States |
| Clinical Research Site | Abingdon | Virginia | 24210 | United States |
| Clinical Research Site | Richmond | Virginia | 23225 | United States |
| Clinical Research Site | Milwaukee | Wisconsin | 53209 | United States |
| ID | Term |
|---|---|
| D029424 | Pulmonary Disease, Chronic Obstructive |
| ID | Term |
|---|---|
| D008173 | Lung Diseases, Obstructive |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |
| D002908 | Chronic Disease |
| D020969 | Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided